secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001683168-23-008159
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma Q3 net loss $4.5M; Berubicin enrollment at 239, interim data Dec 2023
--------------------------------------------------------------------------------

- Net loss of $4.5M vs $3.4M in Q3 2022; R&D expenses rose to $3.4M on clinical progress.
- Cash at Sept 30 was $0.9M; raised $2.6M in October via warrant/ATM; expects to fund operations through Q4 2023.
- Enrollment in potentially pivotal Berubicin GBM study reached 239 patients; full enrollment expected Dec 2023.
- Topline data from interim analysis expected in December 2023; 45 of 60 trial sites activated across US and Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/0001683168-23-008159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-008159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer